| Literature DB >> 25407570 |
Manuel Ignacio Monge García1,2, Manuel Gracia Romero3, Anselmo Gil Cano4, Hollmann D Aya5, Andrew Rhodes6, Robert Michael Grounds7, Maurizio Cecconi8.
Abstract
INTRODUCTION: Functional assessment of arterial load by dynamic arterial elastance (Eadyn), defined as the ratio between pulse pressure variation (PPV) and stroke volume variation (SVV), has recently been shown to predict the arterial pressure response to volume expansion (VE) in hypotensive, preload-dependent patients. However, because both SVV and PPV were obtained from pulse pressure analysis, a mathematical coupling factor could not be excluded. We therefore designed this study to confirm whether Eadyn, obtained from two independent signals, allows the prediction of arterial pressure response to VE in fluid-responsive patients.Entities:
Mesh:
Year: 2014 PMID: 25407570 PMCID: PMC4271484 DOI: 10.1186/s13054-014-0626-6
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1An illustrative example of the arterial pressure and aortic blood flow recordings is shown. Both signals are integrated into the esophageal Doppler system for analysis: the arterial pressure waveform from the patient’s bedside monitor and the aortic blood flow from the Doppler probe. Dynamic arterial elastance was calculated as the ratio between pulse pressure variation and stroke volume variation. All variables are automatically calculated by the Doppler monitor, which combines the arterial pressure analysis with the usual aortic blood flow measurements.
Characteristics and demographic data
|
|
|
|---|---|
| Age (yr) | 62.7 ± 14.4 |
| Sex (men/women) | 31/22 |
| Weight (kg) | 81 ± 23 |
| Height (cm) | 167 ± 8 |
| APACHE II score at admission | 21 ± 5 |
| Plasma lactate level at admission (mmol/L) | 1.9 (1.21 to 3.12) |
| ICU mortality rate, | 16 (30%) |
| Vasoactive drugs at time of inclusion | |
| Norepinephrine, | 30; 0.19 ± 0.14 |
| Dobutamine, | 13; 5 ± 2 |
| Analgesia and sedative drugs | |
| Fentanyl, | 28; 1.55 ± 0.57 |
| Remifentanil, | 20; 0.14 ± 0.06 |
| Midazolam, | 32; 0.10 ± 0.04 |
| Propofol, | 3; 1.25 (1 to 2) |
| Morphine, | 1; 1.8 |
| Ventilator settings | |
| Tidal volume (ml/kg predicted body weight) | 8 (6 to 10) |
| Respiratory rate (breaths/min) | 19 (18 to 20) |
| Total PEEP (cmH2O) | 8 (6 to 10) |
| Acute circulatory failure origin, | |
| Postoperative hypovolemia | 7 (13%) |
| Hemorrhagic shock | 4 (8%) |
| Anoxic encephalopathy | 2 (4%) |
| Toxic poisoning | 2 (4%) |
| Sepsis/septic shock | 32 (60%) |
| Abdominal | 18 |
| Pulmonary | 8 |
| Urological | 2 |
| Neurological | 3 |
| Other | 1 |
aValues are expressed as mean ± SD, median (25th to 75th percentile) or absolute numbers, as appropriate. APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU: intensive care unit; PEEP: positive end-expiratory pressure.
Effects of volume expansion in hemodynamic variables according to mean arterial pressure increase
|
|
|
| |
|---|---|---|---|
| CO, L/min | |||
| Responders | 4.9 ± 2.2 | 5.8 ± 2.5c | 0.581 |
| Non-responders | 5.9 ± 2.3 | 6.8 ± 2.6c | |
| Heart rate, beats/min | |||
| Responders | 91 ± 21 | 86 ± 19c | 0.036 |
| Non-responders | 92 ± 17 | 90 ± 17c | |
| SV, ml | |||
| Responders | 56 ± 24 | 69 ± 26c | 0.971 |
| Non-responders | 65 ± 27 | 77 ± 33c | |
| CPO, W | |||
| Responders | 0.7 ± 0.3d | 1.0 ± 0.4c | <0.001 |
| Non-responders | 0.9 ± 0.3 | 1.1 ± 0.4c | |
| MAP, mmHg | |||
| Responders | 67 ± 15d | 80 ± 18c | <0.001 |
| Non-responders | 74 ± 12 | 76 ± 12c | |
| SAP, mmHg | |||
| Responders | 102 ± 18d | 128 ± 22c | <0.001 |
| Non-responders | 113 ± 18 | 118 ± 20* | |
| DAP, mmHg | |||
| Responders | 51 ± 13 | 57 ± 14c | <0.001 |
| Non-responders | 55 ± 11 | 55 ± 11 | |
| PP, mmHg | |||
| Responders | 51 ± 17 | 70 ± 20c | <0.001 |
| Non-responders | 58 ± 15 | 64 ± 17c | |
| PPV, % | |||
| Responders | 18 ± 7d | 9 ± 5c | <0.001 |
| Non-responders | 11 ± 5 | 8 ± 4c | |
| SVV, % | |||
| Responders | 17 ± 8 | 15 ± 7c | 0.135 |
| Non-responders | 18 ± 7 | 15 ± 5c |
aResponders are defined by a mean arterial pressure (MAP) increase ≥10%). Data are expressed as mean ± SD. b P-values refer to group (responder vs. non-responder) and time (preinfusion vs. postinfusion) interaction using analysis of variance for repeated measurements. c P <0.05 vs. before volume expansion. † P <0.05 vs. non-responders. CO, Cardiac output; CPO, Cardiac power output (mean arterial pressure × cardiac output/451); DAP, Diastolic arterial pressure; MAP, Mean arterial pressure; PP, Pulse pressure (systolic pressure minus diastolic pressure); PPV, Arterial pulse pressure variation; SAP, Systolic arterial pressure; SV, Stroke volume; SVV, Stroke volume variation.
Figure 2Individual changes in cardiac output and mean arterial pressure after fluid administration.
Effects of fluid administration on static and dynamic arterial load variables according to mean arterial pressure increase
|
|
|
| |
|---|---|---|---|
| Eadyn | |||
| Responders | 1.04 ± 0.28c | 0.62 ± 0.27d | <0.001 |
| Non-responders | 0.60 ± 0.14 | 0.59 ± 0.23 | |
| Ea, mmHg/ml | |||
| Responders | 1.89 ± 0.77 | 1.89 ± 0.68 | <0.001 |
| Non-responders | 1.82 ± 0.76 | 1.58 ± 0.62d | |
| C, ml/mmHg | |||
| Responders | 1.11 ± 0.36 | 0.99 ± 0.34d | <0.001 |
| Non-responders | 1.17 ± 0.57 | 1.27 ± 0.60d | |
| SVR, dyn∙s∙cm−5 | |||
| Responders | 1282 ± 572 | 1293 ± 548 | <0.001 |
| Non-responders | 1192 ± 545 | 1050 ± 469d |
aResponders were defined as mean arterial pressure increase ≥10% after fluid administration. Data are expressed as mean ± SD. b P-values refer to group (responders vs. non-responders) and time (preinfusion vs. postinfusion) interaction using analysis of variance for repeated measurements. c P <0.0001 vs. non-responders. d P <0.0001 vs. before volume expansion. C, Net arterial compliance; Ea, Effective arterial elastance; Eadyn, Dynamic arterial elastance; SVR, Systemic vascular resistance.
Figure 3Distribution of individual values (open circles) and mean ± SD (lines) of arterial load variables before fluid administration in pressure responders. The dashed line represents the optimal cutoff for dynamic arterial elastance corresponding to maximum Youden index, and dotted lines depict the “gray zone” calculated from bootstrapped 95% confidence interval (0.72 to 0.88). MAP-R, Mean arterial pressure responders defined by increase ≥10%; MAP-NR, Mean arterial pressure non-responders defined by increase <10%. *P <0.0001 for MAP-R vs. MAP-NR.
Figure 4Linear regression analysis of the relationship between preinfusion dynamic arterial elastance (Ea ) and changes in arterial pressure induced by fluid administration. DAP: diastolic arterial pressure; MAP: mean arterial pressure; SAP: systolic arterial pressure; PP: arterial pulse pressure.
Figure 5Comparison of receiver operating characteristic curves for testing the ability of static and dynamic arterial load variables to detect a mean arterial pressure increase ≥10% after volume administration. Dynamic arterial elastance (Eadyn) = area under the receiver operating characteristic curve (AUC): 0.94 (95% CI: 0.86 to 0.98); effective arterial elastance (Ea) = AUC: 0.53 (95% CI: 0.42 to 0.65); systemic vascular resistance (SVR) = AUC: 0.55 (95% CI: 0.44 to 0.66); net arterial compliance (C) = AUC: 0.51 (95% CI: 0.39 to 0.62); preinfusion MAP = AUC: 0.62 (95% CI: 0.50 to 0.72).